Phase II study of sunitinib in men with advanced prostate cancer
Michaelson M, Regan M, Oh W, Kaufman D, Olivier K, Michaelson S, Spicer B, Gurski C, Kantoff P, Smith M. Phase II study of sunitinib in men with advanced prostate cancer. Annals Of Oncology 2009, 20: 913-920. PMID: 19403935, PMCID: PMC2674960, DOI: 10.1093/annonc/mdp111.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAngiogenesis InhibitorsAngiogenic ProteinsAntineoplastic Agents, PhytogenicDocetaxelDrug Resistance, NeoplasmHumansIndolesMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsProtein Kinase InhibitorsPyrrolesRadiographySunitinibTaxoidsTime FactorsTreatment OutcomeConceptsCastration-resistant prostate cancerProstate cancerPhase II study of sunitinibSoluble vascular endothelial growth factor receptor-2Group AInhibitors of tyrosine kinase receptorsSerum markers of angiogenesisTolerability of sunitinibTreated with sunitinibAdvanced prostate cancerPhase II studyStudy of sunitinibEffects of sunitinibSecondary end pointsVascular endothelial growth factor receptor 2Placental growth factorCommon adverse effectsEndothelial growth factor receptor 2Platelet-derived growth factor-AAMarkers of angiogenesisPost-treatment declinesTyrosine kinase receptorsOn-target effectsPSA declineStable PSA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply